Companies › LaNova Medicines
7 active drug programs in 10 registered trials: 7 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LM-108 Anti-CCR8 monoclonal antibody | CCR8 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Advanced Solid Tumor | Aug 2028 |
| LM-24C5 Anti-CEACAM5 antibody or antibody-drug conjugate | CEACAM5 | Phase 2 | Advanced Solid Tumor Cancer; Advanced Solid Tumor | Dec 2026 |
| LM-168 | – | Phase 2 | Advanced Solid Tumor; Advanced Solid Tumours | Aug 2027 |
| LM-299 | – | Phase 1 | Malignant Tumors | Dec 2026 |
| LM-101 | – | Phase 1 | Malignant Tumors | Jan 2027 |
| LM-350 | – | Phase 1 | Malignant Tumors | Jun 2028 |
| LM-2417 | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05518045 | LM-108 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2026 |
| NCT06650566 | LM-299 | Phase 1 | Malignant Tumors | Oncology | Dec 2026 |
| NCT06187402 | LM-24C5 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05615974 | LM-101 | Phase 1 | Malignant Tumors | Oncology | Jan 2027 |
| NCT06868199 | LM-168 | Phase 1 | Advanced Solid Tumours | Oncology | Aug 2027 |
| NCT07669415 | LM-168 | Phase 2 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07387081 | LM-24C5 | Phase 2 | Advanced Solid Tumor Cancer | Oncology | May 2028 |
| NCT07112222 | LM-350 | Phase 1 | Malignant Tumors | Oncology | Jun 2028 |
| NCT07362186 | LM-108 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Oncology | Aug 2028 |
| NCT06682780 | LM-2417 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2028 |
MediLink Therapeutics (Suzhou) Chipscreen Biosciences Servier Bio-Innovation Kumquat Biosciences Vividion Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.